Table 1 Patients characteristics.

	Gender	Diagnosis	Age at Initial Diagnosis	Disease Site involvement		Prior therapy lines	Prior HSCT	Age at enrollment	Therapy before CAR T	Response to therapy before CAR T	Disease status pre LD	Disease sites prior to CAR T	Pre-LD LDH (U/L)	Pre LD Platelet (K/µL)	Pre LD Neutrophil (per µL)
	Gender	Diagnosis	Age at Initial Diagnosis	BM	CNS	Prior therapy lines	Prior HSCT	Age at enrollment	Therapy before CAR T	Response to therapy before CAR T	Disease status pre LD	Disease sites prior to CAR T	Pre-LD LDH (U/L)	Pre LD Platelet (K/µL)	Pre LD Neutrophil (per µL)
1	M	Burkitt	3.4	+	+	3		3.7	Blina.	PR	MRD	BM	220	122	1650
2	M	Burkitt	7.9			2		8.9	ICE	CR->relapse	*	*
3	M	Burkitt	12.2	+		1		13.2	BFM90	CR->relapse	Active	Pancreas, skin, BM	830	191	1790
4	M	Burkitt	17.8			3		18.8	R-VICI	NR	Active	Peritoneum	929	221	7790
5	F	Burkitt	3.2	+	+	2		6.4	R-ICE	CR	NED	–	281	216	3210
6	F	Burkitt	7.4		+	2		8.3	R-ICE	CR	NED	–	251	235	2750
7	M	Burkitt	5.5	+		2		6.2	R-ICE	PR	Active	BM	3695	28	1320
8	M	DLBCL	5.6			3	+	7.4	Auto-HSCT	CR->relapse	Active	Mediastinum, Lungs	214	160	610
9	F	PMBCL	14.1			3		15.0	BV+Nivo	NR	Active	Mediastinum	394	349	3110
10	F	PMBCL	16.7			2		17.5	BV+Nivo	NR	Active	Mediastinum, Kidneys	301	269	6230
11	M	PMBCL	11.5	+		3		17.5	BV+Nivo	PR	Active	Mediastinum, BM, Kidneys, Pancreas, skull	261	231	2160
12	M	PMBCL	16.7			2		17.6	BV+Nivo	PR	Active	Mediastinum, Lungs	246	266	3070
13	M	DLBCL/ PMBCL	11.2			2		12.4	R-ICE	PR	Active	Mediastinum	427	307	5050

DLBCL diffuse large B-cell lymphoma, PMBCL primary mediastinal B-cell lymphoma, BM bone marrow, CNS central nervous system, HSCT hematopoietic stem cell transplantation, LD lymphodepletion, LDH lactate dehydrogenase, Blina blinatumomab, R-ICE rituximab, ifosphamide, carboplatin, etoposide, R-VICI rituximab, vincristine, idarubicin, ifosfamide, carboplatin, and dexamethasone, BV+Nivo brentuximab vedotin + nivolumab, CR complete response, PR partial response, NR non response, MRD minimal residual disease, NED no evidence of disease.
* Pt.2 passed away prior to lymphodepletion while CAR-T cell were being manufactured.

Quick links

Search